BOULDER, Colo., May 7, 2026
Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its muscular dystrophy and cardiovascular clinical programs, including positive long-term data for sevasemten in Becker muscular dystrophy and upcoming key milestones for its hypertrophic cardiomyopathy pipeline. The biotechnology company emphasized continued momentum across multiple late-stage and mid-stage therapeutic programs targeting serious muscle and heart diseases with significant unmet medical need.
The company announced that long-term clinical data demonstrated sustained functional stabilization in patients with Becker muscular dystrophy treated with sevasemten for up to 3.5 years, marking one of the first investigational therapies to show extended disease stabilization in this rare neuromuscular disorder. Edgewise also confirmed that pivotal top-line results from the global GRAND CANYON Phase III study are expected during the fourth quarter of 2026, potentially supporting the company’s first regulatory marketing application.
Sevasemten Shows Promising Long-Term Becker Data
According to Edgewise, data presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference showed that participants receiving sevasemten maintained stable physical function over extended follow-up periods despite the progressive decline typically associated with Becker muscular dystrophy. Researchers reported that the findings contrasted sharply with expected natural disease progression and further reinforced earlier clinical observations supporting the therapy’s potential efficacy.
The company also highlighted additional analyses demonstrating a favorable cardiac safety profile for sevasemten, including no adverse effects on left ventricular ejection fraction or NT-proBNP biomarkers over 12 months of treatment. Investigators observed positive cardiac trends among adult participants compared with placebo controls, supporting the broader therapeutic potential of the investigational agent.
Advertisement
The ongoing GRAND CANYON Phase III trial is evaluating the safety and efficacy of sevasemten over an 18-month period using the North Star Ambulatory Assessment as the primary clinical endpoint. Edgewise stated that the study is highly powered to demonstrate statistically significant functional improvement compared with placebo and could potentially position sevasemten as the first approved targeted therapy for Becker muscular dystrophy, a rare disease currently lacking approved treatments.
The company is also continuing development programs in Duchenne muscular dystrophy through its Phase II LYNX and FOX clinical trials evaluating sevasemten in pediatric populations, including patients previously treated with gene therapies.
Cardiovascular Programs Expand Clinical Momentum
In addition to neuromuscular disease development, Edge wise reported continued advancement of its cardiovascular pipeline. The company plans to release 12-week data during the second quarter of 2026 from the CIRRUS-HCM Phase II study evaluating EDG-7500, a novel cardiac sarcomere modulator being developed for obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).
The company intends to initiate a Phase III clinical program for EDG-7500 in the second half of 2026 as it expands into broader cardiovascular disease indications. Edgewise is also advancing EDG-15400, another oral cardiac sarcomere modulator designed for heart failure and diastolic dysfunction, currently undergoing Phase I clinical evaluation. The company expects to begin a Phase II trial in patients with heart failure with preserved ejection fraction (HFpEF) later this year.
Executives stated that the company’s deep expertise in muscle physiology continues driving development of next-generation therapeutics for rare neuromuscular and cardiac diseases. Analysts view Edgewise as one of the emerging biotechnology companies focused on highly specialized muscle biology therapies targeting underserved patient populations.
Financial Position Supports Ongoing Development
Edgewise reported approximately $499.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing substantial financial resources to support continued clinical development and regulatory activities.
Research and development expenses increased to $42.7 million during the first quarter, primarily driven by expanded clinical activities involving EDG-7500 and EDG-15400, while net loss for the quarter totaled $49 million.
With multiple late-stage catalysts approaching and several programs advancing simultaneously, Edgewise Therapeutics continues positioning itself as a significant player in the development of innovative therapies for muscle and cardiovascular diseases.
Source: Edgewise Therapeutics press release
